An interventional study of Diet and exercise. and Diet. in Endometrial Cancer, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by National Institute of Cancerología · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Endometrial Neoplasms with a site in Mexico — 4 open to participants now, 7 under way, 4 of them phase 3. Endometrial Neoplasms · Mexico.
Among the 10 studies in Endometrial Neoplasms with a site in Mexico, this one is one of 2 that started in 2025, is the only one with no phase, and was the 10th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →4 of the 10 studies in Endometrial Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Mexico, United States, Argentina and 31 more countries
Ages 18+ · Women only
Daiichi Sankyo · Sites in Mexico, United States, Argentina and 15 more countries
Ages 18+
National Institute of Cancerología · Sites in Mexico
Ages 18+ · Women only
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 805 across the 9 interventional studies, 64 across the 1 observational. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 6 most frequent:
National Institute of Cancerología is the lead sponsor of 39 studies on the registry; 10 are open to participants now.
National Institute of Cancerología has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Endometrial Neoplasms with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07025213National Institute of CancerologíaMetabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery. | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Endometrial Neoplasms with a site in Mexico, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
Endometrial cancer is one of the diseases linked to obesity in women. In Mexico, about 7.6 women out of every 100,000 are diagnosed with this type of cancer, and nearly three-quarters of these women have obesity. Many women with endometrial cancer also have a condition called sarcopenic obesity, where muscle loss happens but might not be easy to identify. Researchers believe that certain molecules in the blood could help identify the health of muscles. Exercise helps muscles stay strong and healthy by affecting these molecules. For women with cancer, staying active can help maintain muscle mass, which is important for better recovery and health outcomes. This project focuses on an exercise program for women with locally advanced endometrial cancer who will be treated surgically at the National Cancer Institute of Mexico (INCan).
What We Think Will Happen:
Women with endometrial cancer who participate in a program combining physical activity and healthy eating will gain more muscle strength and function compared to those who don't exercise. We expect these changes to be connected to healthier levels of certain molecules in the blood, showing less muscle breakdown and less inflammation. We also believe these women will have better control of blood sugar and fats.
Our Main Goal:
To find out how physical activity and diet affect muscle health and metabolism in women with endometrial cancer, and to compare these changes to women who don't participate in the exercise program.
How We Will Do It:
We will measure molecules related to muscle health in the blood. We will also assess muscle size, strength, and how well the muscles work. Then, we will look for connections between these muscle changes and the blood molecules. We want to see if improvements in muscle are linked to better recovery from surgery and better health outcomes. If so, these blood molecules might help doctors monitor muscle health. We hope that the exercise program will help women recover better and improve their quality of life.
How We Will Analyze the Data:
We will describe the data we collect and compare the group that exercises to the group that doesn't. We will use statistics to see if the differences are meaningful. We will also analyze the relationship between muscle health and blood markers. Advanced methods will help us identify which molecules and measurements best explain the changes seen. The results will be carefully reviewed using specialized software.
What We Hope to Find:
We aim to show that blood tests can help identify muscle health and how it improves with exercise. This could lead to earlier detection of muscle loss and better management through exercise programs. Ultimately, this work hopes to improve the health and well-being of women facing endometrial cancer.
What is Endometrial Cancer (EC)?
Type I (most common): linked to hormones like estrogen, usually has a better outlook.
-Type II: less common and not related to estrogen.
What Increases the Risk of EC?
How Does Obesity Affect EC Treatment?
Importance of Diet
What Patients and Families Should Know
What Healthcare Providers Should Know
General Objective:
To evaluate the metabolic effect of a physical activity and dietary intervention in patients with endometrial cancer who are candidates for staging surgery, and its association with musculoskeletal changes, in comparison with a control group of patients who do not receive the physical activity intervention.
Hypothesis Patients with endometrial cancer who engage in physical activity and follow a dietary intervention will show an increase in skeletal muscle mass, strength, and function compared to women who do not engage in physical activity. This change will be associated with a serum amino acid profile, an increase in molecules related to anabolism, a decrease in those related to catabolism, and changes in the cytokine profile indicating a trend toward reduced inflammation. Additionally, women who undergo the physical activity intervention will show improvements in glucose and lipid metabolism compared to those who do not engage in physical activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will only receive recommendations to follow an anti-inflammatory diet.
Other: Diet.
The intervention group will receive both dietary and exercise interventions.
Other: Diet and exercise.
The intervention group will receive recommendations to follow an anti-inflammatory diet. In addition, they will be instructed to increase their level of physical activity and will be asked to attend the institute to carry out a supervised exercise routine.
The comparison group will be instructed to follow the anti-inflammatory diet intervention only.
Changes in serum tyrosine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum histidine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum lysine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum phenylalanine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum glutamic acid concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum methionine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum aspartic acid concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum proline concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum serine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum threonine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum isoleucine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum valine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum leucine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum glycine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum cystine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum alanine concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum IL-6 concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum IL-10 concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum TGF-betha concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum TNF-alpha concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum creatine kinase concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum irisin concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum decorin concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in serum musclin concentration after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks
Changes in total blood cholesterol after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in blood LDL cholesterol after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in blood HDL cholesterol after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in blood triglycerides after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in blood glucose after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in insulin after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in glycosylated hemoglobin after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in muscle mass after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in hand strength after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Changes in physical function after the physical activity plus diet intervention, compared to patients receiving diet only.
Time frame: From enrollment to the end of treatment at 4 weeks.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 26 months is below that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cancerología